Bicara Therapeutics Inc (NASDAQ:BCAX) concluded the trading at $12.42 on Friday, March 14 with a fall of -6.97% from its closing price on previous day.
Taking a look at stock we notice that its last check on previous day was $13.35 with its price kept floating in the range of $12.01 and $14.04 on the day. Considering stock’s 52-week price range provides that BCAX hit a high price of $28.09 and saw its price falling to a low level of $11.10 during that period. Over a period of past 1-month, stock came subtracting -6.05% in its value.
With its current market valuation of $675.84 million, Bicara Therapeutics Inc is set to declare its quarterly results on 2024-Nov-11. Analysts are in estimates of -0.28 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to -2.64 for current year with estimates of that growing to -1.46 in next year.
Digging deeper we become aware of the PEG ratio of the BCAX stock which is currently positioned at 0. It further provides that stock’s current price level is -8.73% away from its 20-day simple moving average and is -7.28% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 42.77 while volatility remained at 13.82% over the past week which changes to 11.25% when measuring it over the past month. Average true range or ATR is currently at 1.47. In predicting price targets of as low as $35 and as high as $35, analysts are in agreement on assigning the stock over the next 12 months average price target of $35. Stock’s current price level is -181.8% above from estimated low price target while it is -181.8% below the estimated high; and even if the BCAX’s share succeeded to reach the median price of $35, then the outlook of -181.8% could come to the excitement of the investors.
Having a second look at Bicara Therapeutics Inc (NASDAQ:BCAX) provides that stock’s average daily trading volume for 3 months was 501.76K, while it jumped to 743040 when we calculate an average volume for past 10 days. Number of outstanding shares of the stock stood at 54.41 million.
The percentage of outstanding shares held by the insiders is 43.23% while it is 55.58% for the institutional holders. In February the standing of shares short improved as it was 4.08 million in the previous month. Subtraction of -28.70% by stock’s current price to its year-to-date value in last trading session is likely to be increasing investors’ interest in the stock as it is hinting an extended uptrend.
